## **RESEARCH HIGHLIGHTS**

Nature Reviews Molecular Cell Biology | AOP, published online 14 May 2008; doi:10.1038/nrm2418

## In the news

## 'SKIN DEEP' GOES TO A NEW DEPTH

Mice can sense the level of O<sub>2</sub> in their surroundings through their skin and can thereby regulate the ability of their blood to carry O2, report Randall Johnson of the University of California, San Diego, USA, and colleagues, in Cell. Although it is well known that amphibians can breath in part through their skin, this paper shows for the first time that epidermal gas exchange is also important for mammalian physiology. Moreover, this finding, which flies in the face of the general notion that the skin is merely a protective envelope, "brings home in spades the theme of whole-body physiology," says Franklin Bunn, a Harvard University professor who was not involved in this study (The Scientist, 17 April 2008).

The transcription factor hypoxiainducible factor-1 $\alpha$  (HIF-1 $\alpha$ ) has previously been linked to the mammalian response to low levels of O<sub>2</sub>. Specifically, HIF-1 $\alpha$  activity initiates a cascade that increases production of erythropoietin (EPO) in the kidney and liver, causing increased production of red blood cells and increased ability of the blood to carry O<sub>2</sub>. To examine this pathway in greater detail, the authors knocked out the Hif-1 $\alpha$  gene in the skin of a mouse line, exposed the mice to low levels of O, and measured EPO levels. "When we knock out Hif-1 $\alpha$ , the net result is that the animal's response to a hypoxic environment is basically blunted almost to the point of not happening," says Johnson (The Scientist, 17 April 2008). Conversely, knockout of the von Hippel-Lindau (VHL) factor in the skin, which has opposing activity to HIF-1 $\alpha$ , resulted in increased EPO production.

Notably, this finding may have important therapeutic implications, especially if human skin also senses environmental O<sub>2</sub> levels. "EPO administration is a multi-billion dollar drug market for the treatment of all sorts of diseases involving low red blood cell counts," says Johnson (ScienceDaily, 22 April 2008). Asher Mullard